Future imaging-pathological correlation studies of these three tau tracers conducted on material from individuals scanned while alive will very valuable to conduct detailed quantitative assessments for the reliable interpretation of change of tau pathology burden in AD and the relationship with the clinical progression of the disease. The gene discussed is MAPT; the disease is Alzheimer disease.